You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed

Showing 1 - 25 of 7,775
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed Ovarian Cancer Trial (Fluzoparib, Apatinib)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Oct 7, 2023

Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)

Active, not recruiting
  • Relapsed Adult ALL
  • Relapsed Adult AML
  • Changchun, Jilin, China
    First Hospital of Jilin University
Nov 19, 2023

Refractory Cancer, Relapsed Cancer Trial in Weston (Drug Sensitivity Test (DST))

Not yet recruiting
  • Refractory Cancer
  • Relapsed Cancer
  • Drug Sensitivity Test (DST)
  • Weston, Florida
    Lerner College of Medicine: Cleveland Clinic Florida
Sep 1, 2023

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

PET-CT Imaging in Relapsed/Refractory Acute Leukemias

Not yet recruiting
  • B Cell
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 4, 2023

    Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Suzhou, Jiangsu, China
      First Affiliated Hospital, Soochow University
    Jul 31, 2023

    Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

    Not yet recruiting
    • Relapsed/Refractory B-Cell Lymphoma
    • (no location specified)
    Jul 10, 2023

    Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Relmacabtagene Autoleucel Injection
    • (no location specified)
    Apr 13, 2023

    Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis Trial (SAR445514)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Amyloid Light-chain Amyloidosis
    • (no location specified)
    Apr 20, 2023

    Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Sep 20, 2023

    Relapsed or Refractory Multiple Myeloma Trial (Talquetamab)

    Available
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Mar 6, 2023

    Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

    Recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Beijing, Beijing, China
      Han wei dong
    Jun 14, 2023

    Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)

    Not yet recruiting
    • Relapsed and Refractory Multiple Myeloma
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Sep 15, 2023

    Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

    Not yet recruiting
    • Relapsed/Refractory Large B-cell Lymphoma
    • (no location specified)
    Oct 6, 2023

    Refractory/Relapsed Autoimmune Hemolytic Anemia Trial in Tianjin (Zanubrutinib)

    Not yet recruiting
    • Refractory/Relapsed Autoimmune Hemolytic Anemia
    • Tianjin, Tianjin, China
      Regenerative Medicine Center
    Aug 27, 2023

    Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

    Recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • infusion of JY231 injection
    • Guangzhou, Guangdong, China
      Guangdong Second Provincial General Hospital
    Sep 17, 2023

    Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

    Active, not recruiting
    • Relapsed or Refractory Diffuse Large B-cell Lymphoma
    • BEBT-908 for injection
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Oct 8, 2023

    Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • ISB 2001
    • Benowa, Queensland, Australia
      Pindara Private Hospital
    May 18, 2023

    Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • YTS104 Cells injection
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Jun 13, 2023

    Acute Myeloid Leukemia Trial (MCBC regimen, Bu/Cy regimen)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • MCBC regimen
    • Bu/Cy regimen
    • (no location specified)
    Nov 13, 2023

    CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

    Not yet recruiting
    • CD19-positive Relapsed or Refractory B-cell Malignancies
    • UTAA09 cells for infusion
    • +2 more
    • Hefei, Anhui, China
      The First Affiliated Hospital of USTC (AnHui Provincial Hospital
    Oct 13, 2023

    Relapsed or Refractory Lymphomas, Advanced Solid Tumor Trial in Los Alamitos (LP-284)

    Not yet recruiting
    • Relapsed or Refractory Lymphomas
    • Advanced Solid Tumor
    • Los Alamitos, California
      Cancer and Blood Specialty Clinic
    Nov 9, 2023

    Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

    Recruiting
    • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
    • thiotepa combined with pomalidomide
    • Nanjing, Jiangsu, China
      Jiangsu Province People's Hospital.
    Jun 27, 2023

    Relapsed/Refractory B-cell Malignancies Trial (AC676)

    Not yet recruiting
    • Relapsed/Refractory B-cell Malignancies
    • (no location specified)
    Mar 27, 2023